Beautiful Virgin Islands

Monday, Sep 01, 2025

China Mulls Mixing Different COVID-19 Vaccines To Improve Efficacy Of Jabs

China Mulls Mixing Different COVID-19 Vaccines To Improve Efficacy Of Jabs

Authorities have to "consider ways to solve the issue that efficacy rates of existing vaccines are not high", Chinese media outlet The Paper reported.
China is considering the mixing of different Covid-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert has told a conference.

Authorities have to "consider ways to solve the issue that efficacy rates of existing vaccines are not high", Chinese media outlet The Paper reported, citing Gao Fu, the head of the Center for Disease Control and Prevention.

His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country's vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world.

China has administered around 161 million doses since vaccinations began last year -- most people will require two shots -- and aims to fully inoculate 40 percent of its 1.4 billion population by June.

But many have been slow to sign up for jabs, with life largely back to normal within China's borders and domestic outbreaks under control.

Gao has previously stressed the best way to prevent the spread of Covid-19 is vaccination, and said in a recent state media interview that China aims to vaccinate 70 percent to 80 percent of its population between the end of this year and mid-2022.

At the conference in Chengdu on Saturday, Gao added that an option to overcome the efficacy problem is to alternate the use of vaccine doses that tap different technologies.

This is an option that health experts outside China are studying as well.

Gao said experts should not ignore mRNA vaccines just because there are already several coronavirus jabs in the country, urging for further development, The Paper reported.

Currently, none of China's jabs conditionally approved for the market are mRNA vaccines, but products that use the technology include those by US pharma giant Pfizer and German start-up BioNTech, as well as by Moderna.

China has four conditionally approved vaccines, whose published efficacy rates remain behind rival jabs by Pfizer-BioNTech and Moderna, which have 95 percent and 94 percent rates respectively.

China's Sinovac previously said trials in Brazil showed around 50 percent efficacy in preventing infection and 80 percent efficacy in preventing cases requiring medical intervention.

Sinopharm's vaccines have efficacy rates of 79.34 percent and 72.51 percent respectively, while the overall efficacy for CanSino's stands at 65.28 percent after 28 days.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Chinese and Indian Leaders Pursue Amity Amid Global Shifts
European Union Plans for Ukraine Deployment
ECB Warns Against Inflation Complacency
Concerns Over North Cyprus Casino Development
Shipping Companies Look Beyond Chinese Finance
Rural Exodus Fueling European Wildfires
China Hosts Major Security Meeting
Chinese Police Successfully Recover Family's Savings from Livestream Purchases
Germany Marks a Decade Since Migrant Wave with Divisions, Success Stories, and Political Shifts
Liverpool Defeat Arsenal 1–0 with Szoboszlai Free-Kick to Stay Top of Premier League
Prince Harry and King Charles to Meet in First Reunion After 20 Months
Chinese Stock Market Rally Fueled by Domestic Investors
Israeli Airstrike in Yemen Kills Houthi Prime Minister
Ukrainian Nationalist Politician Andriy Parubiy Assassinated in Lviv
Corporate America Cuts Middle Management as Bosses Take On Triple the Workload
Parents Sue OpenAI After Teen’s Death, Alleging ChatGPT Encouraged Suicide
Amazon Faces Lawsuit Over 'Buy' Label on Digital Streaming Content
Federal Reserve Independence Questioned Amid Trump’s Push to Reshape Central Bank
British Politics Faces Tumultuous Autumn After Summer of Rebellions and Rising Farage Momentum
US Appeals Court Rules Against Most Trump-Era Tariffs
UK Sought Broad Access to Apple Users’ Data, Court Filing Reveals
UK Bank Shares Dive Over Potential Tax on Sector
Germany’s Auto Industry Sheds 51,500 Jobs in First Half of 2025 Amid Deepening Crisis
Bruce Willis Relocated Due to Advanced Dementia
French and Korean Nuclear Majors Clash As EU Launches Foreign Subsidy Probe
EU Stands Firm on Digital Rules as Trump Warns of Retaliation
Getting Ready for the 3rd Time in Its History, Germany Approves Voluntary Military Service for Teenagers
Argentine President Javier Milei Evacuated After Stones Thrown During Campaign Event
Denmark Confronts U.S. Diplomat Over Covert Trump-Linked Influence in Greenland
Starmer Should Back Away from ECHR, Says Jack Straw
Trump Demands RICO Charges Against George Soros and Son for Funding Violent Protests
Taylor Swift Announces Engagement to NFL Star Travis Kelce
France May Need IMF Bailout, Warns Finance Minister
Chinese AI Chipmaker Cambricon Posts Record Profit as Beijing Pushes Pivot from Nvidia
After the Shock of Defeat, Iranians Yearn for Change
Ukraine Finally Allows Young Men Aged Eighteen to Twenty-Two to Leave the Country
The Porn Remains, Privacy Disappears: How Britain Broke the Internet in Ten Days
YouTube Altered Content by Artificial Intelligence – Without Permission
Welcome to The Definition of Insanity: Germany Edition
Just a reminder, this is Michael Jackson's daughter, Paris.
Spotify’s Strange Move: The Feature Nobody Asked For – Returns
Manhunt in Australia: Armed Anti-Government Suspect Kills Police Officers Sent to Arrest Him
China Launches World’s Most Powerful Neutrino Detector
How Beijing-Linked Networks Shape Elections in New York City
Ukrainian Refugee Iryna Zarutska Fled War To US, Stabbed To Death
Elon Musk Sues Apple and OpenAI Over Alleged App Store Monopoly
2 Australian Police Shot Dead In Encounter In Rural Victoria State
Vietnam Evacuates Hundreds of Thousands as Typhoon Kajiki Strikes; China’s Sanya Shuts Down
UK Government Delays Decision on China’s Proposed London Embassy Amid Concerns Over Redacted Plans
A 150-Year Tradition to Be Abolished? Uproar Over the Popular Central Park Attraction
×